TY - JOUR
T1 - Scale − Up and economic evaluation of the atomized rapid injection solvent extraction process
AU - Kurniawansyah, Firman
AU - Mammucari, Raffaella
AU - Tandya, Andrian
AU - Foster, Neil R.
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017
Y1 - 2017
N2 - The Atomized Rapid Injection Solvent Extraction (ARISE) process is a new technique for the production of micron-size particles using a supercritical antisolvent. Scale-up of the process can be achieved simply by maintaining the antisolvent/solvent ratios and pressure differentials while increasing batch volumes. In this work, two model compounds, para-coumaric acid (PCA) and hydroxypropyl-β-cyclodextrin (HPβCD), were processed using ARISE at different operating scales. The batch size for PCA varied between 0.2 g/batch and 1.6 g/batch, while the batch size of HPβCD varied from 0.8 g/batch to 13.9 g/batch. The economic evaluation of the process was based on production rates between 2 and 10 t/a, which are typical for high-specialty grade chemicals. Capital investment and production costs were estimated using the scaling–exponential method. Investment costs were estimated between 190 and 950 US$/kg of product while production costs were calculated between 52 and 255 US$/kg of product (year 2015). The figures indicate that ARISE can be economically viable for the manufacturing of specialty chemicals as pharmaceuticals.
AB - The Atomized Rapid Injection Solvent Extraction (ARISE) process is a new technique for the production of micron-size particles using a supercritical antisolvent. Scale-up of the process can be achieved simply by maintaining the antisolvent/solvent ratios and pressure differentials while increasing batch volumes. In this work, two model compounds, para-coumaric acid (PCA) and hydroxypropyl-β-cyclodextrin (HPβCD), were processed using ARISE at different operating scales. The batch size for PCA varied between 0.2 g/batch and 1.6 g/batch, while the batch size of HPβCD varied from 0.8 g/batch to 13.9 g/batch. The economic evaluation of the process was based on production rates between 2 and 10 t/a, which are typical for high-specialty grade chemicals. Capital investment and production costs were estimated using the scaling–exponential method. Investment costs were estimated between 190 and 950 US$/kg of product while production costs were calculated between 52 and 255 US$/kg of product (year 2015). The figures indicate that ARISE can be economically viable for the manufacturing of specialty chemicals as pharmaceuticals.
KW - ARISE
KW - Economic evaluation
KW - Micronization
KW - Scale-up
KW - Supercritical fluids
UR - http://www.scopus.com/inward/record.url?scp=85016761426&partnerID=8YFLogxK
U2 - 10.1016/j.supflu.2017.03.006
DO - 10.1016/j.supflu.2017.03.006
M3 - Article
AN - SCOPUS:85016761426
SN - 0896-8446
VL - 127
SP - 208
EP - 216
JO - Journal of Supercritical Fluids
JF - Journal of Supercritical Fluids
ER -